Agilent announces cell analysis workflow automation for immuno-oncology, virology, and vaccine development markets

Santa clara, calif.--(business wire)--agilent technologies inc. (nyse: a) today announced their xcelligence rtca ht (real-time cell analysis high-throughput) platform now integrates with the biotek biospa 8 automated incubator.
A Ratings Summary
A Quant Ranking